Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Long

Showing results (291-300 of 703) with videos related to

Pageof 71
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 31, 2017
Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017Selma Ugurel, Joachim Röhmel, Paolo A Ascierto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanomaJ H Lee, G V Long, S Boyd, et al.
Cancers|August 14, 2020
Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNARussell J Diefenbach, Jenny H Lee, Alexander M Menzies, et al.
The Australasian Journal of Dermatology|February 21, 2022
Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanomaThomas E Pennington, Cathy Yunjia Zhao, Andrew J Colebatch, et al.
Oncoimmunology|October 21, 2016
Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanomaE Liniker, A M Menzies, B Y Kong, et al.
Plos One|April 3, 2020
Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma modelKelly J McKelvey, Amanda L Hudson, Ramyashree Prasanna Kumar, et al.
European Journal of Cancer (Oxford, England : 1990)|December 29, 2015
Survival of patients with advanced metastatic melanoma: The impact of novel therapiesSelma Ugurel, Joachim Röhmel, Paolo A Ascierto, et al.
Journal for Immunotherapy of Cancer|July 11, 2025
Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915Georgina V Long, Hao Tang, Keyur Desai, et al.
Biomarker Research|November 21, 2017
Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patientsSu Yin Lim, Jenny H Lee, Sarah J Welsh, et al.
Oncoimmunology|February 1, 2020
Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patientsTuba N Gide, Ines P Silva, Camelia Quek, et al.
Pageof 71

Showing results (291-300 of 703) with videos related to

Sort By:
Pageof 71
European Journal of Cancer (Oxford, England : 1990)|July 31, 2017
Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017Selma Ugurel, Joachim Röhmel, Paolo A Ascierto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanomaJ H Lee, G V Long, S Boyd, et al.
Cancers|August 14, 2020
Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNARussell J Diefenbach, Jenny H Lee, Alexander M Menzies, et al.
The Australasian Journal of Dermatology|February 21, 2022
Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanomaThomas E Pennington, Cathy Yunjia Zhao, Andrew J Colebatch, et al.
Oncoimmunology|October 21, 2016
Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanomaE Liniker, A M Menzies, B Y Kong, et al.
Plos One|April 3, 2020
Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma modelKelly J McKelvey, Amanda L Hudson, Ramyashree Prasanna Kumar, et al.
European Journal of Cancer (Oxford, England : 1990)|December 29, 2015
Survival of patients with advanced metastatic melanoma: The impact of novel therapiesSelma Ugurel, Joachim Röhmel, Paolo A Ascierto, et al.
Journal for Immunotherapy of Cancer|July 11, 2025
Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915Georgina V Long, Hao Tang, Keyur Desai, et al.
Biomarker Research|November 21, 2017
Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patientsSu Yin Lim, Jenny H Lee, Sarah J Welsh, et al.
Oncoimmunology|February 1, 2020
Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patientsTuba N Gide, Ines P Silva, Camelia Quek, et al.
Pageof 71